Ghcl Buyback 2025 vs Nectar Lifesciences Buyback 2025

Comparison between Ghcl Buyback 2025 and Nectar Lifesciences Buyback 2025.

Buyback Details

Ghcl Buyback 2025 is a Tender Offer buyback proposed to list at BSE, NSE while Nectar Lifesciences Buyback 2025 is a Tender Offer proposed to list at BSE, NSE.

 Ghcl Ltd.Nectar Lifesciences Ltd.
LogoGhcl Buyback 2025 LogoNectar Lifesciences Buyback 2025 Logo
Type of BuybackTender OfferTender Offer
Listing AtBSE, NSEBSE, NSE
Face Value₹10 per share₹1 per share
Buyback Price₹725 per share₹27 per share
Issue Size41,37,931 shares3,00,00,000 shares
Issue Size (Amount)₹300.00 Crores₹81.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders78 Equity Shares out of every 893 Fully paid-up Equity Shares held on the Record Date.6,20,690
General Category for all other Eligible Shareholders9 Equity Shares out of every 181 Fully paid-up Equity Shares held on the Record Date.35,17,241
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,32,51,651
General Category for all other Eligible Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,67,48,349
RegistrarMUFG Intime India Pvt.Ltd.Kfin Technologies Ltd.
Lead ManagersSystematix Corporate Services Ltd.Master Capital Services Ltd.
Necessity of the buyback

The Buyback is a capital allocation decision taken by the Company. The Buyback will help the Company to distribute a part of the surplus cash to its shareholders holding Equity Shares thereby, optimizing returns to the shareholders and enhancing the overall shareholders’ value in longer term and improving the return on equity and earnings per shares.

  • The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders.
  • The buyback will help the company to optimize the capital structure;
  • The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved. The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as "Small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations.
  • The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue; and
  • The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.

Buyback Timetable

Ghcl Buyback 2025 and Nectar Lifesciences Buyback 2025 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Ghcl Buyback 2025 Buyback record date is Nov 14, 2025. Nectar Lifesciences Buyback 2025 Buyback record date is Dec 24, 2025.

 Ghcl Ltd.Nectar Lifesciences Ltd.
Record DateNov 14, 2025Dec 24, 2025
Offer Open DateNov 20, 2025Dec 31, 2025
Offer Closure DateNov 26, 2025Jan 06, 2026
Last date for receipt of tender formsNov 28, 2025Jan 06, 2026
Finalisation of buybackDec 01, 2025Jan 12, 2026
Last Date for settlment of bidsDec 02, 2025Jan 13, 2026
Last Date for extinguishment of sharesDec 11, 2025Jan 22, 2026

Financial Details and Other Relevent Information

Comparison of Ghcl Buyback 2025 and Nectar Lifesciences Buyback 2025 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

 Ghcl Ltd.Nectar Lifesciences Ltd.
Financial

Ghcl Limited Financial Information (Restated Consolidated)

Ghcl Limited's revenue decreased by 7% and profit after tax (PAT) dropped by 21% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended31 Mar 202531 Mar 202431 Mar 2023
Assets4,185.393,769.565,133.41
Total Income3,271.223,498.824,584.53
Profit After Tax624.15793.901,141.57
NET Worth3,483.002,970.043,933.88
Reserves and Surplus3,315.542,882.773,846.31
Amount in ₹ Crore

Company Financials (Restated Consolidated)

Nectar Lifesciences Ltd.'s revenue decreased by 1% and profit after tax (PAT) dropped by 2376% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Income11.301,674.971,698.661,566.85
Profit After Tax-1.01-113.684.99-24.18
NET Worth716.87956.111,069.251,064.59
Reserves and Surplus694.44933.681,046.821,042.17
Total Borrowing458.85582.02635.54753.83
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jan-2025 758.85 461.80 605.40
Jan-2023 647.80 439.25 540.53
Jan-2022 696.20 475.75 586.14

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.75 14.67
Oct-2025 16.01 13.31 14.26
Sep-2025 17.03 14.07 15.15
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jan-2025 758.50 461.25 605.46
Jan-2023 647.80 438.40 540.71
Jan-2022 694.55 477.75 586.49

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.71 14.64
Oct-2025 15.76 13.10 14.18
Sep-2025 16.99 14.03 15.12

Compare with others

Compare:

Ghcl Buyback 2025 and Nectar Lifesciences Buyback 2025